Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials
Open accessThe DOI matches its Crossref record; 129 of the 137 references it cites were found in a registry or an index; 14 of the 57 sources its claims cite were checked for support.
Abstract
BACKGROUND: Findings of substantial remaining morbidity in treated major depressive disorder (MDD) led us to review controlled trials of treatments aimed at preventing early relapses or later recurrences in adults diagnosed with MDD to summarize available data and to guide further research. METHODS: Reports (n = 97) were identified through systematic, computerized literature searching up to February 2015. Treatment versus control outcomes were summarized by random-effects meta-analyses. RESULTS: In 45 reports of 72 trials (n = 14 450 subjects) lasting 33.4 weeks, antidepressants were more effective than placebos in preventing relapses (response rates [RR] = 1.90, confidence interval [CI]: 1.73-2.08; NNT = 4.4; p < 0.0001). In 35 reports of 37 trials (n = 7253) lasting 27.0 months, antidepressants were effective in preventing recurrences (RR = 2.03, CI 1.80-2.28; NNT = 3.8; p < 0.0001), with minor differences among drug types. In 17 reports of 22 trials (n = 1 969) lasting 23.7 months, psychosocial interventions yielded inconsistent or inconclusive results. CONCLUSIONS: Despite evidence of the efficacy of drug treatment compared to placebos or other controls, the findings further underscore the substantial, unresolved morbidity in treated MDD patients and strongly encourage further evaluations of specific, improved individual and combination therapies (pharmacological and psychological) conducted over longer times, as well as identifying clinical predictors of positive or unfavorable responses and of intolerability of long-term treatments in MDD.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found that antidepressants significantly reduce relapse and recurrence in adults with major depressive disorder compared with placebo, with long-term maintenance treatment showing the largest pooled effect. Psychosocial interventions yielded inconsistent and generally weaker evidence, though some benefit appeared in patients with multiple prior episodes.
Key findings
- In 45 reports of 72 continuation trials (n = 14,450; mean 8.35 months), antidepressants were more effective than placebo in preventing relapse: RR = 1.90 (95% CI 1.73–2.08), NNT = 4.4 (3.8–5.2), p < 0.0001; relapse risk averaged 23.3% with continued antidepressant vs 49.4% after discontinuation.
- In 35 reports of 37 long-term trials (n = 7,253; mean 26.8 months), antidepressants were effective in preventing recurrence: RR = 2.03 (95% CI 1.80–2.28), NNT = 3.8 (3.3–4.6), p < 0.0001; 32/37 (86.5%) trials showed significant superiority of active drug over control.
- In 17 reports of 22 psychosocial trials (n = 1,969; mean 23.7 months), pooled RR = 1.39 (95% CI 1.13–1.70), NNT = 6.0 (3.8–14), p = 0.002, but 11/22 (50.0%) comparisons were nonsignificant; benefit was greater in patients with high prior recurrences (RR = 1.63, 95% CI 1.04–2.57) than low prior recurrences (RR = 0.80, 95% CI 0.58–1.09).
- Meta-regression found longer initial treatment before randomization was associated with larger drug–placebo contrast in continuation trials (β = +0.048, CI 0.024–0.073, p < 0.001), and longer long-term treatment duration was associated with larger drug–placebo contrast in maintenance trials (β = +0.104, CI 0.044–0.163, p < 0.001).
Methods
- Systematic review and random-effects meta-analysis of controlled trials identified through computerized searches of PubMed/Medline, Scieverse, SciDirect, and Web-of-Science up to February 2015; 803 reports screened, 146 reviewed in detail, and 97 reports included.
- Inclusion required adults with major depressive disorder, English-language reports, and examination of relapse or recurrence with pharmacological or non-pharmacological treatment; exclusions were bipolar depression, seasonal depression, juvenile depression, and studies only of adverse events or costs.
- Two investigators independently extracted data; analyses computed relative response rates (RRs), rate differences, and number-needed-to-treat (NNT), with meta-regression testing covariates including trial year, size, age, sex proportion, prior episodes, initial treatment weeks, trial duration, and antidepressant type.
Limitations
- Stated by the paper: few well-designed non-pharmacological or combination-treatment studies; follow-up periods ranged from several months to five years (average up to 2 years), with actual times to new episodes usually not reported; many trials used “enriched” designs requiring short-term response, limiting generalizability; many trials discontinued active treatment in barely recovered patients, possibly contributing to inferior placebo outcomes; juvenile and mainly geriatric depression were excluded; some placebo arms were reused in multi-arm trials, though sensitivity analyses showed minor effects; and many studies lacked clinical details on prior episodes, subjective wellness, functioning, and predictors of tolerability or response.
- Evident from the text: psychosocial trials were heterogeneous and half of comparisons were nonsignificant, making conclusions about psychosocial maintenance treatment less secure than those for antidepressants.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Findings from random-effects meta-analysis of 37 controlled, long-term trials (>12 months) of antidepressants vs. placebos in major depression. The pooled ratio (RR) of recurrence risk with placebo vs. antidepressants, of 2.03 [CI: 1.80-2.28]) is highly significant (z-score = 11.7, p < 0.0001).](https://figures.cochat.ai/paper-figures/aeb112a55a4446f3aa7a4372000f0d00/prevention-of-relapse-and-recurrence-in-adults-with-major-depressive-disorder-figure-2.jpg)
Verification
Claims the paper makes
10 Valid · 1 Not valid · 20 Not checked · 55 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Their findings favored ECT added or compared with medicinal treatments (Gagne et al., 2000; Kellner et al., 2006).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Not checked — no full text of the sourcecites Gagne et al., 2000 source
- Disputedcites Kellner et al., 2006 sourceExperimental — accuracy not yet measured
The EFFICACY RESULTS section (page not provided) reports no statistically significant difference between continuation ECT and pharmacotherapy; relapse was 37.1% with ECT versus 31.6% with pharmacotherapy. The COMMENT section likewise says there was no statistical evidence that either treatment had greater efficacy. This study therefore does not support a finding favoring ECT over medication. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Family psychoeducation appeared to be useful long-term in two studies reported from Japan (Shimazu et al., 2011; Shimodera et al., 2012).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion
What the sources say
- Supportedcites Shimazu et al., 2011 source
The Method section identifies this as a study conducted in Japan. The Discussion reports that family psychoeducation significantly reduced relapse of major depression for up to nine months, supporting its usefulness over the study’s follow-up period. This citation accounts for one of the two studies named in the citing sentence. (LLM, conf=0.91)
- Partly supportedcites Shimodera et al., 2012 sourceExperimental — accuracy not yet measured
The Results > Clinical outcomes section reports fewer relapses and more relapse-free days with family psychoeducation during nine months of follow-up in this Japanese trial. But the Discussion explicitly says whether its preventive effect lasts beyond nine months is unknown, so the source does not establish long-term usefulness. This verdict addresses Shimodera et al. only, not the other study cited in the sentence; our copy provides no page numbers. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These failed trials involved antidepressants such as tricyclic antidepressants (Maj et al., 1992), SSRIs (Wilson et al., 2003; Reynolds et al., 2006), the anxiolytic SNRI milnacipran (Rouillon et al., 2000), and a preparation of the plant Hypericum perforatum (St. John’s Wort; Kasper et al., 2008).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Long-Term Antidepressant Treatment
What the sources say
- Not matchedcites Maj et al., 1992
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Wilson et al., 2003 source
The citation to Wilson et al. (2003) is attached to the SSRI example, not to the other drug classes or the count of five trials. In “Analysis of recurrence” (page unavailable), the paper reports no significant difference between sertraline and placebo in preventing recurrence during maintenance treatment. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites Reynolds et al., 2006 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among these, notably, family psychoeducation continued for up to 10 months was examined in two Japanese studies and found to be clinically effective and cost-effective in reducing recurrence risks in major depressive disorder patients (Shimazu et al., 2011; Shimodera et al., 2012).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Partly supportedcites Shimazu et al., 2011 sourceExperimental — accuracy not yet measured
The Discussion reports that four sessions of family psychoeducation significantly reduced relapse compared with treatment as usual, supporting clinical effectiveness. But the Family psychoeducation section says sessions occurred every two weeks, and the Discussion reports outcomes for up to 9 months; the intervention did not continue for up to 10 months. (LLM, conf=0.90)
- Partly supportedcites Shimodera et al., 2012 sourceExperimental — accuracy not yet measured
The Results > Clinical outcomes report fewer relapses with family psychoeducation than with treatment as usual over nine months (2 versus 15). But Methods > Procedure describes four sessions held every two weeks, not psychoeducation continued for up to 10 months; nine months was the follow-up period. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several trials of this treatment method did not provide superior protection against recurrences of depression than control conditions (Kuyken et al., 2008; Bondolfi et al., 2010; Mathew et al., 2010).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Not checked — no full text of the sourcecites Kuyken et al., 2008 source
- Partly supportedcites Bondolfi et al., 2010 sourceExperimental — accuracy not yet measured
The Results report similar relapse rates over 14 months for MBCT plus treatment as usual and treatment as usual alone (29% versus 34% in the intention-to-treat sample), supporting the claim that this trial did not show fewer recurrences. But relapse occurred significantly later among MBCT participants who relapsed, so the unqualified statement that it provided no superior protection omits a benefit the paper reports. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites Mathew et al., 2010 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
51 more claims · 3 with their cited sources checked
Create a free account to see all 86 claims and every source verdict.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sim et al. included various types of maintenance therapy such as antidepressant monotherapy, polypharmacy, combination therapy (e.g., antidepressants plus psychotherapy, electroconvulsive therapy, and lithium) regardless of whether a study continued the same antidepressant used for acute treatment in the maintenance phase or switched to a new one.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, a meta-analysis by Sim et al. showed that 6 of the 15 studies submitted to the FDA by Borges et al. had the same number of subjects as the other published studies included in their meta-analysis.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, they used the data from Borges et al.’s study which risks the possibility of duplicate analysis.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in agreement with clinical studies showing that remitted patients treated with fluoxetine present higher rates of relapse, in comparison with other ADs.30, 31”
From Adult hippocampal neuroplasticity triggers susceptibility to recurrent depression (2017) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most trials recruited patients with depression from specialist mental health services, treated them with antidepressants for 3 to 8 months, and randomly assigned patients who had a response to therapy to continue antidepressant therapy or switch to placebo.”
From Maintenance or Discontinuation of Antidepressants in Primary Care (2021) · cites this paper as [9]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Consistentz = 11.7reported p < .0001 · recomputed p < .001
“(z=11.7, p < .0001”
- Consistentz = 11.7reported p < .0001 · recomputed p < .001
“z = 11.7, p < .0001”
- Consistentz = 3.15reported p = .002 · recomputed p = .002
“(z = 3.15, p = .002”
- Consistentz = 2.14reported p = .03 · recomputed p = .032
“z = 2.14, p = .03”
- Consistentz = 1.41reported p = .16 · recomputed p = .159
“z = 1.41, p = .16”
2 more recomputed tests
Create a free account to see every test the Stats check recomputed.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Psychosocial Treatments
“Ma & Teasdale, 2004 a | 38 | MCT (high) | TAU | 0.98 (0.68–1.26)”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Psychosocial Treatments
“1.4 (1.1–1.9)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Effect of Type of Treatment
“Only TCAs (n = 10) and the pool of SSRIs (n = 11) and SNRIs (n = 7) provided at least 10 trials for meta-analysis, and all yielded similar RR values (2.09, 2.10, and 2.17, respectively).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Effect of Type of Treatment
“SSRIs (2.17) ≥ SNRIs (2.10) ≥ TCAs (2.09)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
“b, long-term antidepressants (2.02) > a, continuation of antidepressants (1.90) > c, long-term psychosocial treatments (1.39)”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
“| RR (95% CI) | 1.90 (1.73–2.08) | 2.03 (1.80-2.28) | 1.39 (1.13–1.70) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Per trial | 189 (138–239) | 188 (131–245) | 124 (92.1–156) |”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
Reported 189 · recomputed 200.694444
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Continuation Trials of Antidepressants
“Montgomery et al., 1998 | Mirtazapine | 387 | 6.78 (3.32–13.9) | 4.2 (5.9–6.8) | 1.04”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Continuation Trials of Antidepressants
“5.9–6.8”
Citations
Cites
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.
Teasdale, J. D., Segal, Z. V., Williams, J. M. G., Ridgeway, V. A., Soulsby, J. M., & Lau, M. A. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.4.615 · Cited by 3,236 · cited 4×
“, 2010), and others found beneficial effects among patients with at least three previous depressive episodes (Teasdale et al., 2000; Ma and Teasdale, 2004).”
BackgroundInfluentialMa, S. H., & Teasdale, J. D. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.1.31 · Cited by 1,390 · cited 10×
“Several of the studies reviewed found that treatment effects appeared to be superior among patients with multiple (especially ≥3) previous episodes of depression (Montgomery et al., 1993; Teasdale et al., 2000; Lepine et al., 2004; Ma and Teasdale, 2004; Kelin et al., 2010).”
BackgroundInfluentialThree-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“Earlier reviews and meta-analyses and recent treatment guidelines for long-term treatment of MDD are generally supportive of treatments continued for several months as well as more than a year, particularly pharmacotherapies (Geddes et al., 2003; Lam et al., 2009; Pilling et al., 2009; Williams et al., 2009; Glue et a…”
MethodMindfulness-based cognitive therapy to prevent relapse in recurrent depression.
Kuyken, W., Byford, S., Taylor, R. S., Watkins, E., Holden, E., White, K., Barrett, B., Byng, R., Evans, A., Mullan, E., et al. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0013786 · Cited by 770 · cited 2×
“Several trials of this treatment method did not provide superior protection against recurrences of depression than control conditions (Kuyken et al., 2008; Bondolfi et al., 2010; Mathew et al., 2010).”
BackgroundPrevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735 · cited 2×
“There is also some evidence that use of CBT during an index episode of acute depression may have long-lasting beneficial effects in limiting risks of relapse or recurrences for up to 2 years after initial remission (Hollon et al., 2005; Dobson et al., 2008).”
BackgroundSackeim, H. A., Haskett, R. F., Mulsant, B. H., Thase, M. E., Mann, J. J., Pettinati, H. M., Greenberg, R. M., Crowe, R. R., Cooper, T. B., & Prudic, J. (2001) · JAMA · doi:10.1001/jama.285.10.1299 · Cited by 686
Reynolds III, C. F., Frank, E., Perel, J. M., Imber, S. D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., et al. (1999) · JAMA · doi:10.1001/jama.281.1.39 · Cited by 659
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Dobson, K. S., Hollon, S. D., Dimidjian, S., Schmaling, K. B., Kohlenberg, R. J., Gallop, R. J., Rizvi, S. L., Gollan, J. K., Dunner, D. L., & Jacobson, N. S. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.76.3.468 · Cited by 560 · cited 1×
“There is also some evidence that use of CBT during an index episode of acute depression may have long-lasting beneficial effects in limiting risks of relapse or recurrences for up to 2 years after initial remission (Hollon et al., 2005; Dobson et al., 2008).”
BackgroundKennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525 · cited 1×
“Earlier reviews and meta-analyses and recent treatment guidelines for long-term treatment of MDD are generally supportive of treatments continued for several months as well as more than a year, particularly pharmacotherapies (Geddes et al., 2003; Lam et al., 2009; Pilling et al., 2009; Williams et al., 2009; Glue et a…”
Shea, M. T. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100026006 · Cited by 509
Treatment of Depression by Drugs and Psychotherapy
KLERMAN, G. L., DIMASCIO, A., WEISSMAN, M., PRUSOFF, B., & PAYKEL, E. S. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.2.186 · Cited by 500
Mynors-Wallis, L. M., Gath, D. H., Lloyd-Thomas, A. R., & Tomlinson, D. (1995) · BMJ · doi:10.1136/bmj.310.6977.441 · Cited by 492
Prevention of Recurrent Depression With Cognitive Behavioral Therapy: Preliminary Findings
Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., & Belluardo, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.816 · Cited by 491 · cited 8×
“…of women participants; (e) estimated counts of previous depressive episodes; (f) initial weeks of treatment prior to randomization; (g) month duration of continuation or long-term trials; (h) type of antidepressant (older agents [TCAs, the atypical agents dothiepin and mianserin, or MAO…”
BackgroundInfluentialExecutive Dysfunction and Long-term Outcomes of Geriatric Depression
Alexopoulos, G. S., Meyers, B. S., Young, R. C., Kalayam, B., Kakuma, T., Gabrielle, M., Sirey, J. A., & Hull, J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.285 · Cited by 486
Maintenance Treatment of Major Depression in Old Age
Reynolds, C. F., Dew, M. A., Pollock, B. G., Mulsant, B. H., Frank, E., Miller, M. D., Houck, P. R., Mazumdar, S., Butters, M. A., Stack, J. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052619 · Cited by 476
Kellner, C. H., Knapp, R. G., Petrides, G., Rummans, T. A., Husain, M. M., Rasmussen, K., Mueller, M., Bernstein, H. J., O’Connor, K., Smith, G., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1337 · Cited by 471 · cited 1×
“Their findings favored ECT added or compared with medicinal treatments (Gagne et al., 2000; Kellner et al., 2006).”
BackgroundLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Segal, Z. V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., & Levitan, R. D. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.168 · Cited by 429 · cited 2×
“However, one trial found it to be about as effective as long-term treatment with an antidepressant (Segal et al., 2010), and others found beneficial effects among patients with at least three previous depressive episodes (Teasdale et al.”
BackgroundFive-Year Outcome for Maintenance Therapies in Recurrent Depression
Kupfer, D. J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100013002 · Cited by 370
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365 · cited 8×
“These treatments involved the use of SNRIs, SSRIs, and other agents with demonstrated short-term efficacy in acute major depressive episodes (Undurraga and Baldessarini, 2012; Baldessarini, 2013).”
BackgroundInfluentialSelf-citationCognitive–behavioral treatment for depression: Relapse prevention.
Gortner, E. T., Gollan, J. K., Dobson, K. S., & Jacobson, N. S. (1998) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.66.2.377 · Cited by 341
Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Cost of depression among adults in England in 2000
Thomas, C. M., & Morris, S. (2003) · British Journal of Psychiatry · doi:10.1192/00-000 · Cited by 310
A Randomized Trial of Relapse Prevention of Depression in Primary Care
Katon, W., Rutter, C., Ludman, E. J., Von Korff, M., Lin, E., Simon, G., Bush, T., Walker, E., & Unützer, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.3.241 · Cited by 295
Jarrett, R. B., Kraft, D., Doyle, J., Foster, B. M., Eaves, G. G., & Silver, P. C. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.4.381 · Cited by 293
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269 · cited 2×
“Currently, pharmacological and non-pharmacological treatments are relatively well established as having at least moderate efficacy for the short-term treatment of acute major depression (Undurraga and Baldessarini, 2012; Baldessarini, 2013; Bauer et al., 2015).”
BackgroundSelf-citationBockting, C. L. H., DELTA Study Group, Schene, A. H., Spinhoven, P., Koeter, M. W. J., Wouters, L. F., Huyser, J., & Kamphuis, J. H. (2005) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.73.4.647 · Cited by 249 · cited 5×
“…was reported; (b) trial size (total number of subjects); (c) mean age of subjects; (d) proportion of women participants; (e) estimated counts of previous depressive episodes; (f) initial weeks of treatment prior to randomization; (g) month duration of continuation or long-term trials; (h) type of…”
BackgroundInfluentialSilverstone, P. H., Ravindran, A., & the Venlafaxine XR 360 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0105 · Cited by 246 · cited 2×
“…>100 0.69 Montgomery et al., 1998 Mirtazapine 387 6.78 (3.32–13.9) 4.2 (5.9–6.8) 1.04 Montgomery et al., 1998 Amitriptyline 386 2.45 (1.56–3.86) 6.0 (4.1–11) 1.68 Feiger et al., 1999 Nefazodone 467 1.96 (1.39–2.75) 6.3 (4.2–12) 2.05 Silverstone and Ravindran, 1999 Fluoxetine 237 1.53…”
InfluentialSertraline in the Prevention of Depression
Doogan, D. P., & Caillard, V. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.160.2.217 · Cited by 245 · cited 1×
“…1989 Imipramine 54 1.69 (1.10–2.60) 3.0 (1.7–11) 1.75 Quitkin et al., 1989 Phenelzine 53 1.93 (1.19–3.12) 2.6 (1.6–6.6) 1.59 Rouillon et al., 1989 Maprotiline 1 141 1.44 (1.13–1.84) 14 (8.2–45) 2.38 Doogan and Caillard, 1992 Sertraline 295 3.50 (2.29–5.36) 3.1 (2.3–4.5) 1.77 Montgomery et al.,…”
InfluentialThe Prophylactic Efficacy of Fluoxetine in Unipolar Depression
Montgomery, S. A., Dufour, H., Brion, S., Gailledreau, J., Laqueille, X., Ferrey, G., Moron, P., Parant-Lucena, N., Singer, L., Danion, J. M., et al. (1988) · British Journal of Psychiatry · doi:10.1192/s0007125000297328 · Cited by 232
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.6.795 · Cited by 228 · cited 2×
“All but five trials (Maj et al., 1992; Rouillon et al., 2000; Wilson et al., 2003; Reynolds et al., 2006; Kasper et al., 2008) yielded statistically superior benefits of active agents over placebo treatments in reducing recurrence risk.”
BackgroundAn evaluation of continuation therapy with tricyclic antidepressants in depressive illness
Mindham, R. H. S., Howland, C., & Shepherd, M. (1973) · Psychological Medicine · doi:10.1017/s0033291700046304 · Cited by 225
Bondolfi, G., Jermann, F., der Linden, M. V., Gex-Fabry, M., Bizzini, L., Rouget, B. W., Myers-Arrazola, L., Gonzalez, C., Segal, Z., Aubry, J.-M., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.07.007 · Cited by 223 · cited 2×
“1992 Tricyclics±Lithium 72 1.22 [0.97–1.52] 6.3 [2.9 to >100] 4.17 OADIG 1993 Dothiepin 69 1.83 [1.01–3.32] 4.0 [2.1–37] 2.19 Kishimoto et al.”
BackgroundInfluentialKane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290090053011 · Cited by 212
Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders
Forte, A., Baldessarini, R. J., Tondo, L., Vázquez, G. H., Pompili, M., & Girardi, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.02.011 · Cited by 203
Self-citationBauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
Montgomery, S. A., & Dunbar, G. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00009 · Cited by 188 · cited 2×
“…was more likely with psychotherapy (Teasdale et al., 2000; Ma and Teasdale, 2004; Bockting et al., 2005, 2009) than with pharmacotherapies (Montgomery and Dunbar, 1993; M Fava et al., 1998; Lepine et al., 2004; Keller et al., 2007a; 2007b; Kocsis et al., 2007; Kuyken et al., 2008;…”
BackgroundKeller, M. B. (1998) · JAMA · doi:10.1001/jama.280.19.1665 · Cited by 184
Bauer, M., Bschor, T., Kunz, D., Berghöfer, A., Ströhle, A., & Müller-Oerlinghausen, B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1429 · Cited by 176
Gagné, G. G., Furman, M. J., Carpenter, L. L., & Price, L. H. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1960 · Cited by 165
Montgomery, S. A., Rasmussen, J. G. C., & Tanghøj, P. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00008 · Cited by 163
(1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810090025004 · Cited by 157
Old Age Depression Interest Group, Jacoby, R., Lunn, A. D., Ardern, M., Bergmann, K., Conway, J., Cooling, N., Davies, G., Fisk, J., Gehlhaar, E., et al. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.2.175 · Cited by 155
Continuation and maintenance treatments for depression in older people
Wilkinson, P., & Izmeth, Z. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006727.pub3 · Cited by 151 · cited 11×
“Most of the pharmacotherapy trials reviewed showed significantly lower rates of relapse or recurrence of depressive episodes among adult patients diagnosed with MDD compared to placebos.”
BackgroundInfluentialFava, M., Alpert, J., Nierenberg, A. A., Mischoulon, D., Otto, M. W., Zajecka, J., Murck, H., & Rosenbaum, J. F. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000178416.60426.29 · Cited by 142
Glen, A. I. M., Johnson, A. L., & Shepherd, M. (1984) · Psychological Medicine · doi:10.1017/s0033291700003068 · Cited by 141
Kok, R. M., Heeren, T. J., & Nolen, W. A. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181ec8085 · Cited by 141 · cited 11×
“Most of the pharmacotherapy trials reviewed showed significantly lower rates of relapse or recurrence of depressive episodes among adult patients diagnosed with MDD compared to placebos.”
BackgroundInfluentialKlein, D. N., Santiago, N. J., Vivian, D., Blalock, J. A., Kocsis, J. H., Markowitz, J. C., McCullough, J. P., Rush, A. J., Trivedi, M. H., Arnow, B. A., et al. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.4.681 · Cited by 138
The economic burden of depression with painful symptoms.
Greenberg, P. E., Leong, S. A., Birnbaum, H. G., & Robinson, R. L. (2003) · PubMed · Cited by 137
Pilling, S., Anderson, I., Goldberg, D., Meader, N., Taylor, C., & groups, O. B. O. T. T. G. D. (2009) · BMJ · doi:10.1136/bmj.b4108 · Cited by 127
Boulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127
Lauritzen, L., Odgaard, K., Clemmesen, L., Lunde, M., Öhrström, J., Black, C., & Bech, P. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb09856.x · Cited by 124 · cited 1×
“Reports were excluded if they concerned: (a) bipolar depression; (b) seasonal depression; (c) juvenile depression; or (d) studied only adverse events or costs.”
BackgroundIllness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123 · cited 1×
“Such treatment-discontinuation, itself, may contribute to inferior outcomes in placebo-arms of trials, especially if treatment-discontinuation is abrupt or rapid (Baldessarini et al., 2010; Baldessarini, 2013; Baldessarini et al., 2015).”
BackgroundMontgomery, S. A., Reimitz, P. E., & Zivkov, M. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803000-00002 · Cited by 122
Continuation and Maintenance Use of Antidepressants in Recurrent Depression
Bockting, C. L. H., ten Doesschate, M. C., Spijker, J., Spinhoven, P., Koeter, M. W. J., & Schene, A. H. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000110056 · Cited by 121
Maintenance Therapy for Chronic Depression: A Controlled Clinical Trial of Desipramine
Kocsis, J. H. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830090013002 · Cited by 121
(1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810090029005 · Cited by 117
Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dunner, D. L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0812 · Cited by 116 · cited 1×
“…counts of previous depressive episodes; (f) initial weeks of treatment prior to randomization; (g) month duration of continuation or long-term trials; (h) type of antidepressant (older agents [TCAs, the atypical agents dothiepin and mianserin, or MAO inhibitors] vs. newer agents [SSRIs or…”
BackgroundBockting, C. L. H., Spinhoven, P., Wouters, L. F., Koeter, M. W. J., Schene, A. H., & DELTA Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04784blu · Cited by 113 · cited 2×
“…(all involving CT or MCT) is that presumably more severely ill patients, with at least three or five pre-trial recurrences of depressive episodes, showed greater responses to treatment than subjects with fewer recurrences (Ma and Teasdale, 2004; Bockting et al., 2005, 2009; Teasdale et al., 2000).”
BackgroundBorges, S., Chen, Y.-F., Laughren, T. P., Temple, R., Patel, H. D., David, P. A., Mathis, M., Unger, E., Yang, P., & Khin, N. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08722 · Cited by 109
Ravindran, A. V., Lam, R. W., Filteau, M. J., Lespérance, F., Kennedy, S. H., Parikh, S. V., & Patten, S. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.040 · Cited by 108 · cited 1×
“Earlier reviews and meta-analyses and recent treatment guidelines for long-term treatment of MDD are generally supportive of treatments continued for several months as well as more than a year, particularly pharmacotherapies (Geddes et al., 2003; Lam et al., 2009; Pilling et al., 2009; Williams et al., 2009; Glue et a…”
MethodKlysner, R., Bent-Hansen, J., Hansen, H. L., Lunde, M., Pleidrup, E., Poulsen, D. L., Andersen, M., & Petersen, H. E. H. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.1.29 · Cited by 106
Continuation Therapy with Amitriptyline in Depression
Coppen, A., Ghose, K., Montgomery, S., Rama Rao, V. A., Bailey, J., & Jorgensen, A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.1.28 · Cited by 103
Depression vulnerability and 5-hydroxytryptophan prophylaxis
van Praag, H. M., & de Haan, S. (1980) · Psychiatry Research · doi:10.1016/0165-1781(80)90049-9 · Cited by 101
Golden, R. N., Nemeroff, C. B., McSorley, P., Pitts, C. D., & Dube, E. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0707 · Cited by 100
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100 · cited 1×
“Earlier reviews and meta-analyses and recent treatment guidelines for long-term treatment of MDD are generally supportive of treatments continued for several months as well as more than a year, particularly pharmacotherapies (Geddes et al., 2003; Lam et al., 2009; Pilling et al., 2009; Williams et al., 2009; Glue et a…”
MethodFamily psychoeducation for major depression: randomised controlled trial
Shimazu, K., Shimodera, S., Mino, Y., Nishida, A., Kamimura, N., Sawada, K., Fujita, H., Furukawa, T. A., & Inoue, S. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.078626 · Cited by 95 · cited 4×
“Among these, notably, family psychoeducation continued for up to 10 months was examined in two Japanese studies and found to be clinically effective and cost-effective in reducing recurrence risks in major depressive disorder patients (Shimazu et al., 2011; Shimodera et al., 2012).”
BackgroundInfluentialPerahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.346 · Cited by 94
Explicit and Implicit Memory in Late-Life Depression
Elderkin‐Thompson, V., Moody, T. D., Knowlton, B. J., Hellemann, G. S., & Kumar, A. A. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181e89a5b · Cited by 93
Mathew, K. L., Whitford, H. S., Kenny, M. A., & Denson, L. A. (2010) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s135246581000010x · Cited by 90
Versiani, M., Mehilane, L., Gaszner, P., Arnaud-Castiglioni, R., & The Metrifonate Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0610 · Cited by 88
The clinical utility of expressed emotion in schizophrenia
Bebbington, P., & Kuipers, L. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05865.x · Cited by 86
Liebowitz, M., Lam, R. W., Lepola, U., Datto, C., Sweitzer, D., & Eriksson, H. (2010) · Depression and Anxiety · doi:10.1002/da.20740 · Cited by 86
Thase, M. E., Nierenberg, A. A., Keller, M. B., & John Panagides for the Relapse Prevention Study Group (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1006 · Cited by 85
Robert, P., Montgomery, S. A., Darcourt, G., Robert, G., Houillon, P., Bouchard, J. M., Tatossian, A., Planche, R., Bourgeois, M., Richou, H., et al. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503001-00006 · Cited by 85 · cited 1×
“…1993b Citalopram 155 3.05 (1.53–6.09) 4.6 (2.8–14) 1.09 Montgomery et al., 1993a Paroxetine 135 2.68 (1.46–4.91) 3.7 (2.4–8.1) 1.27 Mynors-Wallis et al., 1995 Amitriptyline 61 3.10 (1.43–6.73) 2.5 (1.6–5.5) 0.94 Robert and Montgomery, 1995 Citalopram 226 1.76 (1.00–3.10) 9.5 (4.6 to >100) 1.37…”
InfluentialHochstrasser, B., Isaksen, P. M., Koponen, H., Lauritzen, L., Mahnert, F. A., Rouillon, F., Wade, A. G., Andersen, M., Pedersen, S. F., De Swart, J. C. G., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.4.304 · Cited by 85
Lépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83 · cited 2×
“, 2005, 2009) than with pharmacotherapies (Montgomery and Dunbar, 1993; M Fava et al., 1998; Lepine et al., 2004; Keller et al., 2007a; 2007b; Kocsis et al., 2007; Kuyken et al., 2008; Bondolfi et al., 2010; Kelin et al., 2010; Mathew et al., 2010; Thase et al., 2011).”
BackgroundA Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression
Fava, M., Amsterdam, J. D., Deltito, J. A., Salzman, C., Schwaller, M., & Dünner, D. L. (1998) · Annals of Clinical Psychiatry · doi:10.1023/a:1022337927842 · Cited by 81 · cited 1×
“…long-term recurrence rates of depression than with a control condition involving treatment as usual or nonspecific clinical management, again, but the benefits appeared to be limited largely to patients with three or more previous episodes (GA Fava et al., 1998; Bockting et al., 2005, 2009).”
Backgroundvan Beusekom, B. S., van den Broek, W. W., & Birkenhäger, T. K. (2007) · Journal of Ect · doi:10.1097/01.yct.0000263255.98796.30 · Cited by 81
[Recurrence of unipolar depression and efficacy of maprotiline].
Rouillon, F., Phillips, R., Serrurier, D., Ansart, E., & Mj, G. (1989) · PubMed · Cited by 81
Robinson, D. S., Sc, L., Bennett, B., Laux, D. E., Devereaux, E., Kayser, A., CORCELLA, J., & ALBRIGHT, D. (1991) · PubMed · Cited by 79
Cunningham, L. A. (1997) · Annals of Clinical Psychiatry · doi:10.1023/a:1026277907818 · Cited by 78 · cited 5×
“…Montgomery, 1995 Citalopram 226 1.76 (1.00–3.10) 9.5 (4.6 to >100) 1.37 Lauritzen et al., 1996 Paroxetine 58 6.33 (2.11–19.1) 1.8 (1.3–2.9) 0.56 Lauritzen et al., 1996 Imipramine 58 2.11 (1.16–3.86) 2.9 (1.7–9.7) 1.28 Cunningham, 1997 Venlafaxine 278 1.37 (0.99–1.90) 8.9 (4.3 to >100) 2.10…”
BackgroundInfluentialGelenberg, A. J., Trivedi, M. H., Rush, A. J., Thase, M. E., Howland, R., Klein, D. N., Kornstein, S. G., Dunner, D. L., Markowitz, J. C., Hirschfeld, R. M. A., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01971-6 · Cited by 76 · cited 1×
“Thase ME, Gelenberg A, Kornstein SG, Kocsis JH, Trivedi MH, Ninan P, Li T, Pedersen R, Keller M (2011). Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.”
Result(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.1.31 · Cited by 75
Feiger, A. D., Bielski, R. J., Bremner, J., Heiser, J. F., Trivedi, M., Wilcox, C. S., Roberts, D. L., Kensler, T. T., McQuade, R. D., Kaplita, S. B., et al. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199901000-00002 · Cited by 74
Relapse rates with long‐term antidepressant drug therapy: a meta‐analysis
Williams, N., Simpson, A. N., Simpson, K., & Nahas, Z. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1033 · Cited by 74 · cited 1×
“Earlier reviews and meta-analyses and recent treatment guidelines for long-term treatment of MDD are generally supportive of treatments continued for several months as well as more than a year, particularly pharmacotherapies (Geddes et al., 2003; Lam et al., 2009; Pilling et al., 2009; Williams et al., 2009; Glue et a…”
MethodWilson, K. C. M., Mottram, P. G., Ashworth, L., & Abou-Saleh, M. T. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.492 · Cited by 74
Amsterdam, J. D., & Bodkin, J. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239794.37073.70 · Cited by 72 · cited 1×
“…et al., 2002 Paroxetine-IR 428 0.38 (0.21–0.70) >100 1.27 Weihs et al., 2002 Bupropion 828 1.41 (1.20–1.64) 6.7 (4.6–12) 2.64 Fava et al., 2005 Hypericum 88 1.28 (0.81–2.03) 9.0 (3.1 to >100) 1.66 Fava et al., 2005 Fluoxetine 90 1.05 (0.69–1.58) 45 (4.4 to >100) 1.81 Amsterdam and Bodkin…”
InfluentialPhenelzine for chronic depression: a study of continuation treatment.
Harrison, W. M., Rabkin, J. G., Stewart, J. W., McGrath, P. J., TRICAMO, E., & Quitkin, F. M. (1986) · PubMed · Cited by 72
Venlafaxine Versus Placebo in the Preventive Treatment of Recurrent Major Depression
Montgomery, S. A., Entsuah, R., Hackett, D., Kunz, N. R., Rudolph, R. L., & Venlafaxine 335 Study Group (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0307 · Cited by 69
Schmidt, M. E., Fava, M., Robinson, J. M., & Judge, R. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1107 · Cited by 68
Kocsis, J. H., Thase, M. E., Trivedi, M. H., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Dunner, D. L., Hirschfeld, R. M. A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0706 · Cited by 67 · cited 1×
“, 2005, 2009) than with pharmacotherapies (Montgomery and Dunbar, 1993; M Fava et al., 1998; Lepine et al., 2004; Keller et al., 2007a; 2007b; Kocsis et al., 2007; Kuyken et al., 2008; Bondolfi et al., 2010; Kelin et al., 2010; Mathew et al., 2010; Thase et al., 2011).”
BackgroundTerra, J.-L., & Montgomery, S. (1998) · PubMed · Cited by 66
Weihs, K. L., Houser, T. L., Batey, S. R., Ascher, J. A., Bolden-Watson, C., Donahue, R. M. J., & Metz, A. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01317-8 · Cited by 65
Maintenance therapy with amitriptyline: a controlled trial
Stein, M. K., Rickels, K., & Weise, C. (1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.3.370 · Cited by 65
Recurrence of depression after discontinuation of long-term amitriptyline treatment
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.3.325 · Cited by 62
Kornstein, S. G., Bose, A., Li, D., Saikali, K. G., & Gandhi, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1115 · Cited by 60
Entsuah, A. R., Rudolph, R. L., Hackett, D., & Miska, S. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606000-00008 · Cited by 58
Fluoxetine in the Prevention of Depressive Recurrences: A Double-Blind Study
Gilaberte, I., Montejo, A. L., de la Gandara, J., Perez-Sola, V., Bernardo, M., Massana, J., Martin-Santos, R., Santiso, A., Noguera, R., Casais, L., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00009 · Cited by 58
Kasper, S. F., Volz, H., Möller, H. ‐., Dienel, A., & Kieser, M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.006 · Cited by 54 · cited 2×
“All but five trials (Maj et al., 1992; Rouillon et al., 2000; Wilson et al., 2003; Reynolds et al., 2006; Kasper et al., 2008) yielded statistically superior benefits of active agents over placebo treatments in reducing recurrence risk.”
Backgroundvan den Broek, W. W., Birkenhäger, T. K., Mulder, P. G. H., Bruijn, J. A., & Moleman, P. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0213 · Cited by 54
Enhancing the efficacy of antidepressants with psychotherapy
Petersen, T. J. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806064314 · Cited by 53 · cited 1×
“Petersen TJ (2006) Enhancing the efficacy of antidepressants with psychotherapy.”
BackgroundDuration of Initial Antidepressant Treatment and Subsequent Relapse of Major Depression
Baldessarini, R. J., Lau, W. K., Sim, J., Sum, M. Y., & Sim, K. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000263 · Cited by 52 · cited 1×
“…ECT (RR = 3.00) > MAO inhibitor (2.80) > SSRIs (2.17) ≥ SNRIs (2.10) ≥ TCAs (2.09) > various standard antidepressants (1.91) > atypical agents (gepirone, hypericum, mianserin, nefazodone, or quetiapine-ER; 1.72) > lithium (1.39), but all active agent types were significantly superior to placebo.”
BackgroundInfluentialSelf-citationTerra, J. L., & Montgomery, S. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803000-00001 · Cited by 51
Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dünner, D. L., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.040 · Cited by 49
Cox, G. R., Fisher, C. A., De Silva, S., Phelan, M., Akinwale, O. P., Simmons, M. B., & Hetrick, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007504.pub2 · Cited by 48 · cited 1×
“Similarly, computed NNT values ranked inversely in the same order (b, 3.8 a, 4.4 ≤ c, 6.0), as did the rate of trials finding superior outcomes with test treatment versus controls (b, 86.5% > a, 68.1% > c, 50.0%).”
ResultInfluentialMilnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study
Rouillon, F., Warner, B., Pezous, N., & Bisserbe, J. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00002 · Cited by 47 · cited 2×
“All but five trials (Maj et al., 1992; Rouillon et al., 2000; Wilson et al., 2003; Reynolds et al., 2006; Kasper et al., 2008) yielded statistically superior benefits of active agents over placebo treatments in reducing recurrence risk.”
BackgroundEfficacy of Maintenance Electroconvulsive Therapy in Recurrent Depression: A Naturalistic Study
Gupta, S., Tobiansky, R., Bassett, P., & Warner, J. (2008) · The Journal of ECT · doi:10.1097/yct.0b013e3181608bf2 · Cited by 46 · cited 12×
“shorter psychiatric hospitalizations over 8 years compared to similar periods of illness before use of maintenance ECT (Gupta et al., 2008).”
BackgroundInfluentialShimodera, S., Furukawa, T. A., Mino, Y., Shimazu, K., Nishida, A., & Inoue, S. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-40 · Cited by 43 · cited 4×
“Among these, notably, family psychoeducation continued for up to 10 months was examined in two Japanese studies and found to be clinically effective and cost-effective in reducing recurrence risks in major depressive disorder patients (Shimazu et al., 2011; Shimodera et al., 2012).”
BackgroundInfluentialContinuation and maintenance treatments for depression in older people
Wilkinson, P., & Izmeth, Z. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006727.pub2 · Cited by 43
Bschor, T., Berghöfer, A., Ströhle, A., Kunz, D., Adli, M., Müller-Oerlinghausen, B., & Bauer, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00016 · Cited by 42
Björk, K. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb11122.x · Cited by 38 · cited 4×
“Meta-Analysis of Controlled, Long-Term Trials of Psychosocial Treatments for Major Depression Trials Subjects Treatment Controls RR (95% CI) NNT (95% CI) Weight (”
InfluentialRosenthal, J. Z., Boyer, P., Vialet, C., Hwang, E., & Tourian, K. A. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07974 · Cited by 37
Unipolar depression in the elderly
Cook, B. L., Helms, P. M., Smith, R. E., & Tsai, M. (1986) · Journal of Affective Disorders · doi:10.1016/0165-0327(86)90031-5 · Cited by 36
Yıldız, A., Mantar, A., Şimşek, S., Onur, E., Gökmen, N., & Fıdaner, H. (2010) · Journal of Ect · doi:10.1097/yct.0b013e3181c189f7 · Cited by 36
Use of Phenelzine in Continuation Therapy
Davidson, J., & Raft, D. (1984) · Neuropsychobiology · doi:10.1159/000118076 · Cited by 33 · cited 1×
“…8.00 (1.28–50.0) 1.1 (0.8–1.8) 0.23 Kane et al., 1982 Lithium 13 3.50 (1.08–11.3) 1.4 (0.9–2.9) 0.50 Kane et al., 1982 Imipramine 12 1.50 (0.85–2.64) 3.0 (1.4 to >100) 1.37 Davidson and Raft, 1984 Phenelzine 15 6.12 (0.98–38.3) 1.4 (0.9–2.6) 0.23 Lendresse et al., 1985 Nomifensine 143 2.03…”
InfluentialRickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., Germain, J.-M., Leurent, C., & Brisard, C. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c94c4d · Cited by 33
CONTINUATION THERAPY WITH TRICYCLIC ANTIDEPRESSANTS IN DEPRESSIVE ILLNESS
Mindham, R. H. S., Howland, C., & Shepherd, M. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92214-3 · Cited by 33
Relapse Prevention With Gepirone ER in Outpatients With Major Depression
Keller, M. B., Ruwe, F. J. L., Janssens, C. J. J. G., Sitsen, J. M. A., Jokinen, R., & Janczewski, J. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150221.53877.d9 · Cited by 32
Thase, M. E., Gelenberg, A. J., Kornstein, S. G., Kocsis, J. H., Trivedi, M. H., Ninan, P. T., Li, T., Pedersen, R., & Keller, M. B. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.009 · Cited by 28 · cited 1×
“, 2005, 2009) than with pharmacotherapies (Montgomery and Dunbar, 1993; M Fava et al., 1998; Lepine et al., 2004; Keller et al., 2007a; 2007b; Kocsis et al., 2007; Kuyken et al., 2008; Bondolfi et al., 2010; Kelin et al., 2010; Mathew et al., 2010; Thase et al., 2011).”
BackgroundMoclobemide and fluoxetine in the prevention of relapses following acute treatment of depression
Lönnqvist, J. K., Sihvo, S., Syvälahti, E. K. G., Sintonen, H., Kiviruusu, O. H., & Pitkanen, H. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09765.x · Cited by 23
Sheets, E. S., Wilcoxon Craighead, L., Brosse, A. L., Hauser, M., Madsen, J. W., & Edward Craighead, W. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.08.036 · Cited by 16 · cited 1×
“, 2015), and a variety of psychotherapies, including prevalent cognitivebehavioral therapy (Bondolfi et al., 2010; Sheets et al., 2013).”
BackgroundProphylactic effect of mianserin on recurrent depression
Kishimoto, A., Mizukawa, R., Matsuzaki, F., Hazama, H., Kamase, H., Tanaka, K., & Kunimoto, N. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01484.x · Cited by 11 · cited 1×
“Four of the seven failed trials involved standard antidepressants such as mianserin, selective serotonin reuptake inhibitors, tricyclic antidepressant (Maj et al., 1992; Kishimoto et al., 1994; Wilson et al., 2003; Reynolds et al., 2006); one involved the anxiolytic SNRI milnacipran (Rouillon et al.”
BackgroundKelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02374.x · Cited by 11 · cited 2×
“Several of the studies reviewed found that treatment effects appeared to be superior among patients with multiple (especially ≥3) previous episodes of depression (Montgomery et al., 1993; Teasdale et al., 2000; Lepine et al., 2004; Ma and Teasdale, 2004; Kelin et al., 2010).”
BackgroundEfficacy of amineptine in the prevention of relapse in unipolar depression
Ferreri, M., Colonna, L., & Leger, J.-M. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199707003-00007 · Cited by 10 · cited 1×
“Despite generally effective short-term treatments for acute episodes of major depression, many patients experience relapses (early return of symptoms within the expected duration of a current episode, of perhaps 3–12 months) or later recurrences (new episodes) following initial short-term improvement or remission (Geo…”
Background
Research works printed but not linked: 3
- Georgotas, 1985, Affective disorders: pharmacotherapy, Compr Psychiatry, 4, 821
- 10.1176/appi.ajp.131.2.186 · doi:10.1176/appi.ajp.131.2.186
- Lendresse, 1985, Traitement prolongé par nomifensine 75mg dans les états dépressifs neurotiques et reactionnels, Psychiatrie Francaise, 16, 156
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
“A meta-analysis found significant benefit of antidepressants over placebo in maintenance studies of 1 to 12 months (72 trials, N 1⁄4 14450) and 12 months (35 trials, N 1⁄4 7253).(83) Similarly, a review of all 16 maintenance RCTs (N > 4000) submitted to the Food and Drug Administration (FDA) found a 2-fold difference…”
BackgroundMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
“Australian & New Zealand Journal of Psychiatry, 55(1) delivered during the acute phase also have benefits for the maintenance phase: effects of psychological interventions endure at 6 and 12 months (Cuijpers, 2017), and there is some evidence for maintenance of benefits at 2 years (Sim et al., 2016) after treatment ha…”
BackgroundResultInfluentialRecognizing Depression from the Microbiota–Gut–Brain Axis
Liang, S., Wu, X., Hu, X., Wang, T., & Jin, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061592 · Cited by 380
“More than 85% of patients with a first episode will relapse in the next 10 years, and most of the patients have suicidal thoughts, 15–20% of whom will die from suicide [4,5].”
BackgroundLam, R. W., McIntosh, D., Wang, J., Enns, M. W., Kolivakis, T., Michalak, E. E., Sareen, J., Song, W.-Y., Kennedy, S. H., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659416 · Cited by 288
“Clinicians should focus on healthy life strategies, personality vulnerabilities, long-term selfmanagement, and clinical strategies to reduce recurrence.(104,107) In a significant proportion of patients with MDD, maintenance pharmacological, psychological, complementary and alternative medicine, and neurostimulation tr…”
BackgroundPharmacological treatment of adult bipolar disorder
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0044-2 · Cited by 272
Self-citation
Metadata
- Authors
- Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sim, Kang
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-07
- Volume
- 19
- Issue
- 2
- Pages
- pyv076
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4772815
- OpenAlex
- W1913659607
- Semantic Scholar
- cbb9e5ab88cd7ec19a0140daf20022efa2e38311
- Cited by
- 218
- References
- 137
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 22 · 2023: 20 · 2022: 23 · 2021: 38 · 2020: 34 · 2019: 20 · 2018: 10 · 2017: 10 · 2016: 12 · 2015: 1
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Bruce J. Anderson Foundation
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- major depressive disorder, relapse prevention, recurrence prevention, antidepressants, psychosocial interventions, long-term treatment, predictors of treatment response, residual depressive symptoms
- MeSH terms
- Antidepressive Agents, Combined Modality Therapy, Major Depressive Disorder, Humans, Psychotherapy, Recurrence, Controlled Clinical Trials as Topic, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.